Oral Genomics develops and markets advanced inflammatory and genetic testing, multidisciplinary systems, and a new generation of oral care products that address oral biofilm, its microbiome, and oral inflammation specifically. In partnering with key biomedical and healthcare entities, we have developed customized systems and treatment protocols that reduce oral inflammation and its impact on all inflammatory diseases such as cardiovascular disease, cerebrovascular disease, diabetes, rheumatoid arthritis, osteoarthritis, preterm births, dementia, Alzheimer’s disease, pancreatic cancer, and colorectal cancer.